通过PKMYT1激酶抑制,CCNE1放大具有合成致命性
David Gallo1, Jordan T F Young2, Jimmy Fourtounis2
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Nature
|April 21, 2022
概括
放大CCNE1基因会导致抑制PKMYT1激酶的脆弱性. 研究人员开发了RP-6306,该抑制剂在与gemcitabine结合时显示出治疗CCNE1增强癌症的前景.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 在卵巢,子宫和胃食道癌症中,CCNE1位点放大是常见的.
- 高水平的环素E与基因组不稳定性和治疗耐药性相关.
研究的目的:
- 确定CCNE1增强瘤的治疗点.
- 研究PKMYT1激酶抑制的治疗潜力.
主要方法:
- 在CCNE1增强细胞模型中进行了基因组规模的CRISPR- Cas9合成致死性查.
- 开发并测试了选择性PKMYT1抑制剂RP-6306.
主要成果:
- 增加CCNE1剂量使细胞对PKMYT1抑制产生敏感性.
- 在临床前模型中,RP- 6306表现出单剂活性和持久的瘤回归.
- 在过度表达CCNE1的细胞中选择性激活CDK1,导致过早的线粒分裂.
结论:
- 抑制PKMY1代表了对CCNE1增强癌症的有希望的治疗策略.
- 向PKMYT1可以克服与CCNE1放大相关的抵抗机制.
更多相关视频
09:45Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
Published on: March 31, 2015
11.3K
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
681
相关概念视频
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
MAPK Signaling Cascades
6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Amplifying Signals via Enzymatic Cascade
10.9K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
10.9K
cAMP-dependent Protein Kinase Pathways
6.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.7K
Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
